Baker Ellis Asset Management LLC Acquires 200 Shares of Cencora, Inc. (NYSE:COR)

Baker Ellis Asset Management LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 9.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,280 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Baker Ellis Asset Management LLC’s holdings in Cencora were worth $512,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Simon Quick Advisors LLC bought a new stake in Cencora in the fourth quarter valued at approximately $211,000. Crossmark Global Holdings Inc. raised its stake in Cencora by 6.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 39,462 shares of the company’s stock valued at $8,866,000 after buying an additional 2,351 shares during the period. Ballentine Partners LLC raised its stake in Cencora by 4.1% in the fourth quarter. Ballentine Partners LLC now owns 8,880 shares of the company’s stock valued at $1,995,000 after buying an additional 352 shares during the period. UMB Bank n.a. raised its stake in Cencora by 10.6% in the fourth quarter. UMB Bank n.a. now owns 1,248 shares of the company’s stock valued at $280,000 after buying an additional 120 shares during the period. Finally, Client 1ST Advisory Group LLC bought a new position in shares of Cencora during the fourth quarter worth approximately $551,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,187 shares of company stock worth $17,790,912. Insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.8 %

Shares of COR opened at $247.12 on Thursday. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27. The business’s fifty day moving average is $237.26 and its 200-day moving average is $234.40. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $47.76 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 1.51 and a beta of 0.49.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on COR. Wells Fargo & Company lowered their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Evercore ISI increased their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.